• Clearmind Medicine testified at the FDA’s psychedelic hearing in Washington on Sept. 14, 2026, following an FDA invitation.
• Mary-Elizabeth Gifford urged broader patient access, citing trial findings at Yale and Johns Hopkins on non-hallucinogenic neuroplastogens.
• Gifford said eliminating supervised dosing could support scalable treatment through existing primary care and VA systems.
• MEAI, Clearmind’s alcohol use disorder candidate, is in an FDA-authorized Phase 2a trial at Yale and Johns Hopkins.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609170742PRIMZONEFULLFEED9828895) on September 17, 2026, and is solely responsible for the information contained therein.